Moleculin Biotech
MBRX
22 hedge funds and large institutions have $5.26M invested in Moleculin Biotech in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 6 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0% less ownership
Funds ownership: 0.03% → 0.03% (-0%)
6% less capital invested
Capital invested by funds: $5.61M → $5.26M (-$353K)
12% less funds holding
Funds holding: 25 → 22 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$40.7K |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$21.8K |
| 3 |
State Street
Boston,
Massachusetts
|
+$17.2K |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
+$16.1K |
| 5 |
Two Sigma Advisers
New York
|
+$9.17K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$87K |
| 2 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
-$41K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$41K |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$37K |
| 5 |
Goldman Sachs
New York
|
-$22K |
MBRX Hedge Fund Activity: Q1 2022 in Review
22 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2022, worth a combined $5.26M — down 6.3% from $5.61M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of MBRX and 3 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $40.7K. The largest seller was Virtu Financial, exiting entirely with an estimated $87K sold.
- 22 institutional investors held Moleculin Biotech (MBRX) as of Q1 2022, down from 25 in Q4 2021.
- Funds reported $5.26M of Moleculin Biotech stock for Q1 2022, down 6.3% quarter-over-quarter.
- 3 funds opened new Moleculin Biotech positions in Q1 2022 and 6 closed out, a net change of -3 holders.
- The largest Moleculin Biotech buyer in Q1 2022 was Renaissance Technologies, an estimated $40.7K added.
- The largest Moleculin Biotech seller in Q1 2022 was Virtu Financial, an estimated $87K sold.
Based on aggregated 13F filings for Q1 2022.